Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

NewLink Ebola vaccine trial to start in Canada

In Canada, which has no reported cases of Ebola, people are lining up to get in on a clinical trial for an Ebola vaccine.

GSK, Novo earn top marks getting their meds to poor, but more work lies ahead

Big Pharma earned gold stars in 2014, as the industry's top drugmakers did more to get their meds to patients in the world's poorest countries. But despite recent progress, companies still have room to grow in R&D and distribution, the Index notes.

Clovis taps GlaxoSmithKline to team up on lung cancer

Clovis Oncology has signed a deal to test whether its lead drug can make a difference in lung cancer when paired with GlaxoSmithKline's melanoma treatment Mekinist.

GSK, Medidata report on positive pilot of mHealth in clinical trials

GlaxoSmithKline and Medidata have moved mHealth tools one step closer to the clinical trial mainstream. Having run a pilot project, the partners have concluded that mHealth technologies can deliver reliable, FDA-compliant data and improve the clinical trial experience for patients.

Reuters: Apollo interested in GSK's entire $3B package of mature drugs

GlaxoSmithKline has long explored a sale of some $3 billion worth of its older drugs, planning to shed products by geographic region to meet buyers' interests. Now, the company could have a more enticing offer on its hands as private equity firm Apollo Global Management is planning to bid GSK's entire portfolio of drugs, rather than snatch up businesses by region, people familiar with the process told Reuters.

Dendreon bankruptcy weighs on cancer vaccine field

Ever since Dendreon's lackluster Provenge launch, the Washington-based biotech's failures have cast a pall over the troubled cancer vaccine field. And the company's bankruptcy won't help with that.

GlaxoSmithKline's effort to relaunch cancer R&D faces skepticism

GlaxoSmithKline made a high-profile decision to exit the cancer drug field in its recent deal with Novartis, but as Reuters reports, a band of specialists inside GSK still has ambitious plans for developing next-gen therapies.

Glaxo hep C vaccine delivers promising early results

Next-generation hepatitis C drugs may be breaking revenue records now, but eventually a vaccine to prevent the disease could cut into the cash cows' market share. That candidate might come from GlaxoSmithKline, whose hepatitis C vaccine just passed an early test, generating strong and broad immune responses not seen before against the transmissible liver disease.

GlaxoSmithKline heads to the FDA with its next big respiratory bet

GlaxoSmithKline is racing to be the first on the market with a new approach to treating severe asthma, filing U.S. and European applications for the injectable mepolizumab as it jockeys with Teva and AstraZeneca.

UPDATED: AstraZeneca, University of Manchester create new center for advanced drug delivery

The University of Manchester's North West Centre for Advanced Drug Delivery will study drug delivery topics in cancer and other diseases of interest to the  AstraZeneca,  in the latest example of the growing research collaboration between Big  Pharma  and academia.